PUBLISHER: DelveInsight | PRODUCT CODE: 1173634
PUBLISHER: DelveInsight | PRODUCT CODE: 1173634
Bullous Pemphigoid - Epidemiology Forecast - 2032
DelveInsight's " Bullous Pemphigoid (BP)- Epidemiology Forecast-2032" report delivers an in-depth understanding of the BP, historical and forecasted epidemiology as well as the BP market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Geography Covered:
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Study Period: 2019-2032.
Bullous Pemphigoid (BP) Understanding
The DelveInsight's “Bullous Pemphigoid epidemiology report” gives a thorough understanding of the BP, which is a rare skin condition that mainly affects older people. It usually starts with an itchy, raised rash. As the condition develops, large blisters can form on the skin. It is characterized by a poor prognosis due to its high mortality rate and the tendency to relapse. The relapse rate of BP ranges from 27.87% to 53% after disease remission, while the majority of relapses occur early (within 6 months) during remission. Treatment usually helps heal the blisters and ease any itching.
Pruritus is the first symptom of bullous pemphigoid. Skin lesions may not develop for several years. Often, characteristic tense bullae develop on the skin of the trunk and in the flexural and intertriginous areas. Bullae may develop on normal-appearing skin or may be preceded by erythematous or urticarial-appearing plaques. The localized disease may occur at trauma sites, stomas, and anogenital and lower leg areas.
The diagnosis of BP is based on a combination of clinical features, positive direct immunofluorescence (IF) microscopy of perilesional skin, and the detection of specific circulating IgG anti-basement membrane autoantibodies by either indirect IF microscopy studies or by enzyme-linked immunosorbent assay (ELISA). In the majority of cases, the latter tests are sufficient for a correct diagnosis between myopathies, genetic testing remains the standard in distinguishing between disease pathology.
Bullous Pemphigoid (BP) Epidemiology
The epidemiology section provides insights about the historical and current BP patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides a historical as well as forecasted BP epidemiology scenario in the 7MM covering the United States, EU4 countries and the United Kingdom, and Japan from 2019 to 2032.
In 2021, the total diagnosed prevalent cases of BP were approximately 132,200 in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted BP epidemiology [segmented as Diagnosed prevalent cases of BP, Gender-specific diagnosed prevalent cases of BP, Age-specific diagnosed prevalent cases of BP, Severity-specific diagnosed prevalent cases of BP, and Total treated cases of BP in the 7MM covering the United States, EU4 countries and the United Kingdom, and Japan from 2019 to 2032.
Country Wise- Bullous Pemphigoid (BP) Epidemiology
The epidemiology segment also provides the BP epidemiology data and findings across the United States, EU4 and the United Kingdom, and Japan.
KOL- Views
To keep up with the current BP patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the BP domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.
Scope of the Report:
- The report covers the descriptive overview of BP, explaining its causes, symptoms, pathophysiology, and genetic basis.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 countries and the United Kingdom, and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of BP.
- The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
- The report provides the segmentation of the disease epidemiology for 7MM by Diagnosed prevalent cases of BP, Gender-specific diagnosed prevalent cases of BP, Age-specific diagnosed prevalent cases of BP, Severity-specific diagnosed prevalent cases of BP, and Total treated cases of BP in the 7MM covering the United States, EU4 countries and the United Kingdom, and Japan from 2019 to 2032
Report Highlights:
- The companies and academics are working to assess challenges and seek opportunities that could influence BP R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for BP.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Bullous Pemphigoid (BP) Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- BP Epidemiology Segmentation
Key Questions
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of BP?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 and the United Kingdom, and Japan?
- What is the historical BP patient pool in seven major markets covering the United States, EU4 and the United Kingdom, and Japan?
- What would be the forecasted patient pool of BP in seven major markets covering the United States, EU4 and the United Kingdom, and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population about BP?
- Out of all 7MM countries, which country would have the highest prevalent population of BP during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?
Reasons to buy:
- The report will help in developing business strategies by understanding trends shaping and driving the BP Disease market
- To understand the future market competition in the BP Disease market
- Organize sales and marketing efforts by identifying the best opportunities for BP Disease in the US, the EU4 and the UK, and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the BP Disease market
- To understand the future market competition in the BP Disease market
Table of Contents
1. Key Insights
2. Report Introduction
3. BP Market Overview at a Glance
- 3.1. Market Share (%) Distribution of BP in 2019
- 3.2. Market Share (%) Distribution of BP in 2032
4. Executive Summary of BP
- 4.1. Key Events
5. Epidemiology and Market Methodology
6. Disease Background and Overview
- 6.1. Introduction
- 6.2. Types of BP
- 6.3. Triggering Diseases and Factors of BP
- 6.3.1. Drugs
- 6.3.2. Vaccines
- 6.3.3. Infections
- 6.3.4. Physical factors
- 6.3.5. Aging
- 6.3.6. Neurologic Diseases
- 6.3.7. Malignancies
- 6.4. Symptoms of BP
- 6.5. Pathogenesis of BP
- 6.5.1. Role of the complement system
- 6.5.2. Role of inflammatory cells
- 6.5.3. Role of proteolytic enzymes
- 6.5.4. Role of direct mechanisms
- 6.6. Biomarkers of BP
- 6.6.1. Markers of BP activity and severity
- 6.6.2. Markers of BP outcome
7. Diagnosis of BP
- 7.1. History
- 7.2. Clinical Manifestation
- 7.3. Histological Examination
- 7.4. Direct Immunopathological Tests
- 7.5. Indirect Immunofluorescence Tests
- 7.6. ELISA Tests
- 7.7. Differential Diagnosis
- 7.8. Diagnostic Algorithm of BP
- 7.9. Diagnostic Guidelines of BP
- 7.9.1. Guidelines for the management of BP initiated by the European Academy of Dermatology and Venereology (EADV)
- 7.9.2. Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita [EBA])
- 7.9.2.1. Diagnostic criteria
- 7.9.2.2. Disease severity determination criteria
8. Treatment and Management
- 8.1. Systemic steroids
- 8.2. Topical corticosteroids
- 8.3. Azathioprine (AZA)
- 8.4. Anti-inflammatory antibiotics and nicotinamide
- 8.5. Methotrexate
- 8.6. Mycophenolate mofetil
- 8.7. Dapsone and sulfonamides
- 8.8. Intravenous immunoglobulins
- 8.9. Chlorambucil
- 8.10. Cyclophosphamide
- 8.11. Ciclosporin
- 8.12. Other treatments
- 8.12.1. Topical tacrolimus
- 8.12.2. Biologic agents
- 8.12.3. Plasmapheresis and immunoapheresis
- 8.13. Treatment Algorithm for BP
- 8.14. Guidelines for the Treatment of BP
- 8.14.1. Guidelines for the management of BP initiated by the European Academy of Dermatology and Venereology (EADV)
- 8.14.2. British Journal of Dermatology Guidelines for the management of BP
- 8.14.3. Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)
9. Conclusion
10. Epidemiology and Patient Population
- 10.1. Key Findings
- 10.2. Assumptions and Rationale: The 7MM
- 10.3. Epidemiology Scenario in the 7MM
- 10.3.1. Diagnosed prevalent cases of BP in the 7MM
- 10.3.2. Gender-specific diagnosed prevalent cases of BP in the 7MM
- 10.3.3. Age-specific diagnosed prevalent cases of BP in the 7MM
- 10.3.4. Severity-specific diagnosed prevalent cases of BP in the 7MM
- 10.3.5. Total treated cases of BP in the 7MM
- 10.4. Epidemiology Scenario in the US
- 10.4.1. Diagnosed prevalent cases of BP in the US
- 10.4.2. Gender-specific diagnosed prevalent cases of BP in the US
- 10.4.3. Age-specific diagnosed prevalent cases of BP in the US
- 10.4.4. Severity-specific diagnosed prevalent cases of BP in the US
- 10.4.5. Total treated cases of BP in the US
- 10.5. Epidemiology Scenario in the EU4 and the UK
- 10.5.1. Diagnosed prevalent cases of BP in the EU4 and the UK
- 10.5.2. Gender-specific diagnosed prevalent cases of BP in the EU4 and the UK
- 10.5.3. Age-specific diagnosed prevalent cases of BP in the EU4 and the UK
- 10.5.4. Severity-specific diagnosed prevalent cases of BP in the EU4 and the UK
- 10.5.5. Total treated cases of BP in the EU4 and the UK
- 10.6. Epidemiology Scenario in Japan
- 10.6.1. Diagnosed prevalent cases of BP in Japan
- 10.6.2. Gender-specific diagnosed prevalent cases of BP in Japan
- 10.6.3. Age-specific diagnosed prevalent cases of BP in Japan
- 10.6.4. Severity-specific diagnosed prevalent cases of BP in Japan
- 10.6.5. Total treated cases of BP in Japan
11. Unmet Needs
12. Appendix
- 12.1. Bibliography
- 12.2. Acronyms and Abbreviations
- 12.3. Report Methodology
13. DelveInsight Capabilities
14. Disclaimer
15. About DelveInsight
List of Tables
- Table 1: Summary of BP, Market, Epidemiology, and Key Events (2019-2032)
- Table 2: Types of BP
- Table 3: Diagnostic Criteria for Pemphigoid (including epidermolysis bullosa acquisita)
- Table 4: Disease Severity Determination Criteria for Pemphigoid (including epidermolysis bullosa acquisita)
- Table 5: Summary of treatment choice
- Table 6: Diagnosed Prevalent Cases of BP in the 7MM (2019-2032)
- Table 7: Gender-specific Diagnosed Prevalent Cases of BP in the 7MM (2019-2032)
- Table 8: Age-specific Diagnosed Prevalent Cases of BP in the 7MM (2019-2032)
- Table 9: Severity-specific Diagnosed Prevalent Cases of BP in the 7MM (2019-2032)
- Table 10: Total Treated Cases of BP in the 7MM (2019-2032)
- Table 11: Diagnosed Prevalent Cases of BP in the US (2019-2032)
- Table 12: Gender-specific Diagnosed Prevalent Cases of BP in the US (2019-2032)
- Table 13: Age-specific Diagnosed Prevalent Cases of BP in the US (2019-2032)
- Table 14: Severity-specific Diagnosed Prevalent Cases of BP in the US (2019-2032)
- Table 15: Total Treated Cases of BP in the US (2019-2032)
- Table 16: Diagnosed Prevalent Cases of BP in the EU4 and the UK (2019-2032)
- Table 17: Gender-specific Diagnosed Prevalent Cases of BP in the EU4 and the UK (2019-2032)
- Table 18: Age-specific Diagnosed Prevalent Cases of BP in the EU4 and the UK (2019-2032)
- Table 19: Severity-specific Diagnosed Prevalent Cases of BP in the EU4 and the UK (2019-2032)
- Table 20: Total Treated Cases of BP in the EU4 and the UK (2019-2032)
- Table 21: Diagnosed Prevalent Cases of BP in Japan (2019-2032)
- Table 22: Gender-specific Diagnosed Prevalent Cases of BP in Japan (2019-2032)
- Table 23: Age-specific Diagnosed Prevalent Cases of BP in Japan (2019-2032)
- Table 24: Severity-specific Diagnosed Prevalent Cases of BP in Japan (2019-2032)
- Table 25: Total Treated Cases of BP in Japan (2019-2032)
List of Figures
- Figure 1: Epidemiology and Market Methodology
- Figure 2: Understanding of BP
- Figure 3: Triggering Diseases and Factors of BP
- Figure 4: Symptoms of BP
- Figure 5: Pathogenesis of BP
- Figure 6: Diagnostic Approach to the Patient with BP
- Figure 7: Schematic diagram of an ELISA
- Figure 8: Diagnostic Algorithm of BP
- Figure 9: Algorithm for the Treatment of BP
- Figure 10: Diagnosed Prevalent Cases of BP in the 7MM (2019-2032)
- Figure 11: Gender-specific Diagnosed Prevalent Cases of BP in the 7MM (2019-2032)
- Figure 12: Age-specific Diagnosed Prevalent Cases of BP in the 7MM (2019-2032)
- Figure 13: Severity-specific Diagnosed Prevalent Cases of BP in the 7MM (2019-2032)
- Figure 14: Total Treated Cases of BP in the 7MM (2019-2032)
- Figure 15: Diagnosed Prevalent Cases of BP in the US (2019-2032)
- Figure 16: Gender-specific Diagnosed Prevalent Cases of BP in the US (2019-2032)
- Figure 17: Age-specific Diagnosed Prevalent Cases of BP in the US (2019-2032)
- Figure 18: Severity-specific Diagnosed Prevalent Cases of BP in the US (2019-2032)
- Figure 19: Total Treated Cases of BP in the US (2019-2032)
- Figure 20: Diagnosed Prevalent Cases of BP in the EU4 and the UK (2019-2032)
- Figure 21: Gender-specific Diagnosed Prevalent Cases of BP in the EU4 and the UK (2019-2032)
- Figure 22: Age-specific Diagnosed Prevalent Cases of BP in the EU4 and the UK (2019-2032)
- Figure 23: Severity-specific Diagnosed Prevalent Cases of BP in the EU4 and the UK (2019-2032)
- Figure 24: Total Treated Cases of BP in the EU4 and the UK (2019-2032)
- Figure 25: Diagnosed Prevalent Cases of BP in Japan (2019-2032)
- Figure 26: Gender-specific Diagnosed Prevalent Cases of BP in Japan (2019-2032)
- Figure 27: Age-specific Diagnosed Prevalent Cases of BP in Japan (2019-2032)
- Figure 28: Severity-specific Diagnosed Prevalent Cases of BP in Japan (2019-2032)
- Figure 29: Total Treated Cases of BP in Japan (2019-2032)
